Sanofi (NASDAQ:SNY) has agreed to collaborate with
Suzhou, China-based Alphamab Oncology subsidiary Jiangsu Alphamab
Biopharmaceuticals Co., Ltd. to advance the clinical development of
KN026, combined with Taxotere (docetaxel), for the treatment of
HER2-positive breast cancer.
Sanofi has a certain exclusive period to
in-license KN026, an anti-HER2 bispecific antibody, subject to the
achievement of certain clinical milestones.
Enrollment in an open-label study is underway.
Financial terms are not disclosed.
https://seekingalpha.com/news/3581397-sanofi-to-collaborate-alphamab-oncology-in-breast-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.